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Abstract The secretin amino-terminal residues are essential for
high affinity binding to its cognate receptor and for its biological
activity. Mutation of the [Asp3] residue of secretin to [Asn3]
decreased the ligand’s affinity for the rat wild-type receptor 100^
300-fold. Receptor mutations in the transmembrane 2 domain
and the beginning of the first extracellular loop allowed the
identification of three residues involved in recognition of the
[Asp3] residue: D174, K173 and R166. Mutation of K173 and
D174 not only reduced the secretin and [Asn3]secretin affinities,
but also changed the receptor’s selectivity as judged by a
decreased secretin and [Asn3]secretin potency ratio. The most
striking effect was observed when R166 was mutated to Q, D or
L. This led to receptors with a very low affinity for secretin but
an up to 10-fold higher affinity than the wild-type receptor for
[Asn3]secretin. This suggested that R166, highly conserved in
that subgroup of receptor, is a major determinant for the
recognition of the [Asp3] of the ligand.
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1. Introduction
The secretin receptor [1] belongs to a subfamily within the
G protein-coupled receptors that includes the PACAP I [2],
the VIP1/PACAP [3], the Vip2/PACAP [4], the glucagon [5],
the glucagon-like peptide I [6], the growth hormone-releasing
hormone [7], the gastric inhibitory peptide [8], the parathyroid
[9], the calcitonin [10], and the corticotrophin-releasing factor
[11] receptors. There is a high overall sequence homology in
the transmembrane domains of these receptors, and a general
model ^ di¡erent from that of the rhodopsin-like receptor
family ^ for the positioning of these helices has been recently
proposed [12].
The amino-terminal extracellular receptor sequence is
rather long (120 amino acid residues) and is involved in se-
lective ligand recognition [13,14]. In the case of the secretin
receptor, this domain recognizes the central [15] and carboxy-
terminal parts [16] of the ligand.
The amino-terminus of secretin, but also of VIP, PACAP
and GLP-1, is absolutely required for a high a⁄nity interac-
tion with the cognate receptor as well as for a full expression
of the biological activity [17^20]. Furthermore, at least for
secretin, VIP and PACAP, the presence of the lateral chain
of the aspartate in position 3 is necessary for high a⁄nity
interactions with the receptors. Indeed, replacement of
[Asp3] by [Glu3] or [Asn3] in secretin, VIP and PACAP mark-
edly decreases the ligands’ a⁄nities for their cognate recep-
tors. It is thus of interest to identify the receptor’s amino acid
residues that interact with this key residue.
We previously showed that one of the secretin amino-ter-
minal moiety anchoring points was a lysine residue, [Lys173],
located at the end of the second transmembrane helix or at
the beginning of the ¢rst exoloop of the receptor [21]. In the
present work, we investigated the role of amino acids located
in the vicinity of [Lys173] (Fig. 1) and found that a highly
conserved arginine residue [Arg166], located within the second
transmembrane helix, is crucial for the recognition of the
[Asp3] residue of secretin.
2. Materials and methods
The study was performed on the rat secretin receptor.
The products used for recombinant DNA expression and cell cul-
tures have been listed in previous papers [17,21,22]. The mutant re-
ceptors N170CA, D174CV, D174CN, K173CI and K173CQ
were prepared by replacement of a BssHII-BsrGI fragment with a
synthetic duplex constructed from four oligonucleotides encoding
the sequence of the mutant secretin receptor. The duplexes were li-
gated with a BsrGI-NheI fragment and BssHII-NheI pUC19/secretin
receptor vector. The mutant receptors R166CL, R166CD and
R166CQ were constructed as follows: a polymerase chain reaction
fragment was prepared using a primer that encoded the sequence for
the mutation and for the MslI restriction site, and a second primer
that encoded the sequence for the BbsI restriction site. This PCR
fragment was inserted into the TOPO vector (TOPO cloning kit, In-
vitrogen) and sequenced. Then, the MslI-BbsI fragment was obtained
and ligated with the HindIII-MslI secretin receptor fragment and
HindIII-BbsI pUC19/secretin receptor vector.
The mutant cDNAs were then introduced into pRc/RSV mamma-
lian expression vector. The recombinant genes were identi¢ed by re-
striction endonuclease mapping and by sequencing. The plasmids were
transfected in Chinese hamster ovary (CHO) cells and the cells ex-
pressing the protein were selected ¢rst by their resistance to geneticin,
then for their capacity to increase adenylate cyclase activity in re-
sponse to secretin or secretin analogues. Cell cultures, membrane
preparation and adenylate cyclase activity determinations have been
previously detailed [17].
Secretin ^ with an aspartate in position 3 ^ and [Asn3]secretin were
synthesized by solid phase methodology and their conformity and
purity evaluated by capillary electrophoresis, amino acid sequencing
and electrospray mass spectrometry.
3. Results and discussion
The importance of the carboxylic function of [Asp3] in the
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secretin molecule for its receptor recognition was deduced
from the observation that [Asn3]secretin was 100-fold less po-
tent than secretin for secretin receptor occupancy and adeny-
late cyclase activation (Fig. 2, Table 1, [17]). We thus hy-
pothesized that receptor mutants that resulted in the
expression of a protein with a reduced capacity to discrimi-
nate secretin from [Asn3]secretin would give indications on the
residues involved directly or indirectly with the carboxylic
function recognition. We anticipated that the relevant mutant
receptors should display a decreased a⁄nity for secretin ^ a
rather unfavorable condition for binding studies ^ and there-
fore evaluated the receptors’ properties by their capacity to
stimulate adenylate cyclase activity.
We previously demonstrated [17] that the secretin Kact value
is equivalent to its binding Kd value only at low receptor
expression levels : if the receptor concentration is too high,
the agonists’ apparent a⁄nity can be signi¢cantly overesti-
mated in functional studies due to the presence of spare re-
ceptors. We were careful to chose a wild-type receptor clone
expressing a low receptor density (EC50 = Kd). For each mu-
tant receptor we studied at least four di¡erent clones and de-
tailed those with the highest EC50 value and the lowest max-
imal stimulatory e¡ect in the presence of secretin, assuming
that these clones were expressing the lowest receptor density
and thus had EC50 values as close as possible to the receptor
occupancy Kd values. We nevertheless cannot exclude the hy-
pothesis that some of the clones expressing mutant receptors
expressed spare receptors, and that the deleterious e¡ect of
these mutations on secretin recognition was underestimated.
We therefore chose to compare the ratio of the secretin/
[Asn3]secretin EC50 values to evaluate the e¡ect of the recep-
tor mutations in the recognition of the aspartate at position 3
of secretin: spare receptors do not a¡ect the EC50 value ratio
of full agonists.
We ¢rst con¢rmed that the K173CI mutated secretin re-
ceptor [21] had a reduced a⁄nity for secretin and a reduced
capacity to discriminate secretin from [Asn3]secretin and
that similar results were obtained for the K173CQ mutation
(Fig. 3, Table 1). We then mutated the polar amino acid
residues that were assumed to be located in the second trans-
membrane domain on the same face of the helix [12,23,24] and
Fig. 1), namely N170 and R166, as well as D174, which is
adjacent to K173 in the ¢rst extracellular loop.
Mutation of D174CN markedly reduced the receptor’s af-
¢nity for both secretin and [Asn3]secretin, and also the ratio
between the Kact values of secretin and [Asn3]secretin (Fig. 3
and Table 1). Mutation of D174CA could not be investi-
gated as receptor expression could not be detected among
48 clones transfected with the construction and resistant to
geneticin (data not shown). D174 is a highly conserved residue
in this family of receptors and was also found to be essential
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Fig. 1. Schematic representation of a possible alignment [24] of the
TM 2 of the rat secretin receptor. The arrows indicate the amino
acid residues that were mutated.
Fig. 2. Dose-response curves of adenylate cyclase activation in the presence of secretin (b) or [Asn3]secretin (a) on membranes from CHO cells
expressing the rat secretin receptor wild-type (left panel) or mutated R166CQ (right panel). The results are the mean of three determinations.
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for high a⁄nity VIP binding on the VIP1/PACAP receptor
[25]. This residue might be more important for the receptor
structure than for a precise contact between the ligand and the
receptor.
Mutation of N170CA a¡ected neither the receptor a⁄nity
nor its capacity to discriminate secretin from [Asn3]secretin
(Fig. 3 and Table 1). Similar results (not shown) were ob-
tained with the N170CV mutant receptor.
The most spectacular change in receptor selectivity was
observed for the mutation of residue R166 to Q, L or D:
secretin was 500^1000-fold less potent on the mutated than
on the wild-type receptor (Fig. 2 and Table 1), whereas
[Asn3]secretin’s potency was unchanged or increased 10-fold.
Thus, the suppression of the positive charge in position 166
was highly unfavorable for secretin recognition but not for
[Asn3]secretin recognition. We in fact observed lower EC50
values when investigating the e¡ect of [Asn3]secretin on the
R166CL and R166CQ mutants. These results might be ex-
plained by two hypotheses: (1) spare receptors might be
present in the clones studied (see above); (2) it is also possible
that [Asn3]secretin (and secretin) recognizes slightly di¡erent
binding sites in the wild-type and mutant receptors. The dif-
ference must, however, be subtle since both mutant receptors
were capable of activating the adenylate cyclase in response to
agonists: we know that the proper recognition of the amino
acids at positions 1^4 of secretin by the receptor is essential
for receptor activation [17].
Arginine166 is an excellent candidate for a precise contact
point between the ligand and the receptors: (a) this charged
residue is conserved in the whole family of receptors except in
the calcitonin receptor; (b) receptor modeling suggests it to be
rather accessible as its side chain is facing an internal pocket
limited by TM 2, 3, 4, 5, 6 and 7, TM 1 being more largely
exposed to the lipid bilayer [12].
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Table 1
EC50 values for wild-type and mutant secretin receptors
Secretin receptor EC50(nM)
Secretin [Asn3]secretin N3/D3
Wild-type 2 200 100
K173CI 16 200 13
K173CQ 200 900 5
D174CN 125 3800 30
N170CA 2 200 100
R166CQ 1000 30 0.03
R166CLa 400 50 0.125
R166CDa 1500 300 0.2
EC50 values were obtained from dose-response curves of adenylate cyclase activation and established using the Ligand program. Each value was the
mean of three determinations. The S.E.M. values were below 0.1 concentration logarithm units. N3/D3 indicates the ratio between the
[Asn3]secretin and secretin EC50 values.
aIndicates that the maximal e¡ect of secretin was lower than that of [Asn3]secretin.
Fig. 3. Dose-response curves of adenylate cyclase activation in the presence of secretin (b) or [Asn3]secretin (a) on membranes from CHO cells
expressing three mutated secretin receptors: the N170CA (left panel), K173CQ (middle panel) and D174CN (right panel) secretin receptors.
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As the residue is buried relatively deeply in the transmem-
brane domain the present results suggest that the peptide li-
gand, like the small aminergic ligands, may enter into the
receptor to change receptor conformation. The precise local-
ization of secretin on its receptor is far from completely es-
tablished. Considering the large similarities between the secre-
tin, VIP and PACAP receptors, converging studies of di¡erent
research groups have identi¢ed critical regions for peptide
binding. The N-terminal domain and particularly residues
1^10 [26], the C-terminus of the ¢rst extracellular loop [21]
and four residues in the N-terminal half of the second extra-
cellular loop are implicated in ligand recognition and discrim-
ination [27]. The present data demonstrate that the carboxy-
terminal moiety of TM 2 is a major binding site for the ami-
no-terminal sequence of secretin. In view of the conservation
of this receptor region in the secretin receptor family, the
homologous amino acids probably have the same importance
for other ligand-receptor interactions.
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